Base de dados : MEDLINE
Pesquisa : D03.132.327.287.572 [Categoria DeCS]
Referências encontradas : 110 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 11 ir para página                         

  1 / 110 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28300233
[Au] Autor:Liu H; Jia Y
[Ad] Endereço:State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, 38 Xueyuan Road, Beijing 100191, China. yxjia@bjmu.edu.cn.
[Ti] Título:Ergot alkaloids: synthetic approaches to lysergic acid and clavine alkaloids.
[So] Source:Nat Prod Rep;34(4):411-432, 2017 Apr 05.
[Is] ISSN:1460-4752
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Covering: 2000 to 2017Ergot alkaloids are among the most important pharmaceuticals and natural toxins. Significant progress has been achieved in recent years on the research of ergot alkaloids. In this review, we re-introduced the history of ergot alkaloids. Meanwhile, we summarized all the natural products and semi-synthetic derivatives of ergot alkaloids. We also briefly described the biosynthesis and semi-synthesis of ergot alkaloid drugs from raw materials obtained by fermentation. Moreover, we reviewed the advances that have been made in the total synthesis of ergot alkaloids since 2000.
[Mh] Termos MeSH primário: Alcaloides de Claviceps/síntese química
Ácido Lisérgico/síntese química
[Mh] Termos MeSH secundário: Alcaloides de Claviceps/química
Ácido Lisérgico/química
Estrutura Molecular
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Ergot Alkaloids); ITO20DAO7J (Lysergic Acid)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170524
[Lr] Data última revisão:
170524
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170317
[St] Status:MEDLINE
[do] DOI:10.1039/c6np00110f


  2 / 110 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:25887091
[Au] Autor:Thamhesl M; Apfelthaler E; Schwartz-Zimmermann HE; Kunz-Vekiru E; Krska R; Kneifel W; Schatzmayr G; Moll WD
[Ad] Endereço:BIOMIN Research Center, Technopark 1, 3430, Tulln, Austria. michaela.thamhesl@biomin.net.
[Ti] Título:Rhodococcus erythropolis MTHt3 biotransforms ergopeptines to lysergic acid.
[So] Source:BMC Microbiol;15:73, 2015 Mar 28.
[Is] ISSN:1471-2180
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Ergopeptines are a predominant class of ergot alkaloids produced by tall fescue grass endophyte Neotyphodium coenophialum or cereal pathogen Claviceps purpurea. The vasoconstrictive activity of ergopeptines makes them toxic for mammals, and they can be a problem in animal husbandry. RESULTS: We isolated an ergopeptine degrading bacterial strain, MTHt3, and classified it, based on its 16S rDNA sequence, as a strain of Rhodococcus erythropolis (Nocardiaceae, Actinobacteria). For strain isolation, mixed microbial cultures were obtained from artificially ergot alkaloid-enriched soil, and provided with the ergopeptine ergotamine in mineral medium for enrichment. Individual colonies derived from such mixed cultures were screened for ergotamine degradation by high performance liquid chromatography and fluorescence detection. R. erythropolis MTHt3 converted ergotamine to ergine (lysergic acid amide) and further to lysergic acid, which accumulated as an end product. No other tested R. erythropolis strain degraded ergotamine. R. erythropolis MTHt3 degraded all ergopeptines found in an ergot extract, namely ergotamine, ergovaline, ergocristine, ergocryptine, ergocornine, and ergosine, but the simpler lysergic acid derivatives agroclavine, chanoclavine, and ergometrine were not degraded. Temperature and pH dependence of ergotamine and ergine bioconversion activity was different for the two reactions. CONCLUSIONS: Degradation of ergopeptines to ergine is a previously unknown microbial reaction. The reaction end product, lysergic acid, has no or much lower vasoconstrictive activity than ergopeptines. If the genes encoding enzymes for ergopeptine catabolism can be cloned and expressed in recombinant hosts, application of ergopeptine and ergine degrading enzymes for reduction of toxicity of ergot alkaloid-contaminated animal feed may be feasible.
[Mh] Termos MeSH primário: Alcaloides de Claviceps/metabolismo
Ácido Lisérgico/metabolismo
Rhodococcus/metabolismo
[Mh] Termos MeSH secundário: Animais
Biotransformação
Claviceps/metabolismo
Análise por Conglomerados
DNA Bacteriano/química
DNA Bacteriano/genética
DNA Ribossômico/química
DNA Ribossômico/genética
Epichloe/metabolismo
Mamíferos
Dados de Sequência Molecular
Filogenia
RNA Ribossômico 16S/genética
Análise de Sequência de DNA
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (DNA, Bacterial); 0 (DNA, Ribosomal); 0 (Ergot Alkaloids); 0 (RNA, Ribosomal, 16S); ITO20DAO7J (Lysergic Acid)
[Em] Mês de entrada:1603
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150419
[St] Status:MEDLINE
[do] DOI:10.1186/s12866-015-0407-7


  3 / 110 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:25744603
[Au] Autor:Durairaj H; Steury MD; Parameswaran N
[Ad] Endereço:Department of Physiology, Michigan State University, East Lansing, MI 48824, USA.
[Ti] Título:Paroxetine differentially modulates LPS-induced TNFα and IL-6 production in mouse macrophages.
[So] Source:Int Immunopharmacol;25(2):485-92, 2015 Apr.
[Is] ISSN:1878-1705
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that is clinically used for the treatment of depression in human patients. Because of recent reports on the role of serotonin in modulating inflammation and the link between inflammation and depression, we sought to test the effect of paroxetine directly on macrophage response to an inflammatory stimulus. Lipopolysaccharide (LPS) treatment of mouse macrophages significantly enhanced TNFα and IL-6 production. Paroxetine treatment of macrophages, however, significantly inhibited LPS-induced IL-6 production. In contrast, paroxetine enhanced LPS-induced TNFα production in macrophages. These effects of paroxetine were mimicked by fluoxetine, another SSRI. To determine if the effects of paroxetine are mediated via modulation of the 5-HT system, we treated macrophages with 5-HT or 5-HT receptor antagonist (LY215840) in the presence of LPS and/or paroxetine. 5-HT treatment by itself did not affect LPS-induced cytokine production. LY215840, however, reversed paroxetine's effect on LPS-induced TNFα production but not IL-6. To understand the signaling mechanisms, we examined paroxetine's effect on MAPK and NFκB pathways. While paroxetine inhibited LPS-induced IκBα phosphorylation, MAPK pathways were mostly unaffected. Together these data demonstrate that paroxetine has critical but differential effects on IL-6 and TNFα production in macrophages and that it likely regulates these cytokines via distinct mechanisms.
[Mh] Termos MeSH primário: Interleucina-6/metabolismo
Macrófagos/efeitos dos fármacos
Paroxetina/farmacologia
Inibidores da Captação de Serotonina/farmacologia
Fator de Necrose Tumoral alfa/metabolismo
[Mh] Termos MeSH secundário: Animais
Linhagem Celular
Fluoxetina/farmacologia
Lipopolissacarídeos
Ácido Lisérgico/análogos & derivados
Ácido Lisérgico/farmacologia
Macrófagos/metabolismo
Camundongos Endogâmicos C57BL
Serotonina/farmacologia
Antagonistas da Serotonina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Interleukin-6); 0 (Lipopolysaccharides); 0 (Serotonin Antagonists); 0 (Serotonin Uptake Inhibitors); 0 (Tumor Necrosis Factor-alpha); 0 (interleukin-6, mouse); 01K63SUP8D (Fluoxetine); 137328-52-0 (LY 215840); 333DO1RDJY (Serotonin); 41VRH5220H (Paroxetine); ITO20DAO7J (Lysergic Acid)
[Em] Mês de entrada:1601
[Cu] Atualização por classe:161019
[Lr] Data última revisão:
161019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150307
[St] Status:MEDLINE


  4 / 110 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:25513893
[Au] Autor:Gerhards N; Neubauer L; Tudzynski P; Li SM
[Ad] Endereço:Philipps-Universität Marburg, Institut für Pharmazeutische Biologie und Biotechnologie, Deutschhausstrasse 17A, D-35037 Marburg, Germany. nina.gerhards@pharmazie.uni-marburg.de.
[Ti] Título:Biosynthetic pathways of ergot alkaloids.
[So] Source:Toxins (Basel);6(12):3281-95, 2014 Dec 10.
[Is] ISSN:2072-6651
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Ergot alkaloids are nitrogen-containing natural products belonging to indole alkaloids. The best known producers are fungi of the phylum Ascomycota, e.g., Claviceps, Epichloë, Penicillium and Aspergillus species. According to their structures, ergot alkaloids can be divided into three groups: clavines, lysergic acid amides and peptides (ergopeptines). All of them share the first biosynthetic steps, which lead to the formation of the tetracyclic ergoline ring system (except the simplest, tricyclic compound: chanoclavine). Different modifications on the ergoline ring by specific enzymes result in an abundance of bioactive natural products, which are used as pharmaceutical drugs or precursors thereof. From the 1950s through to recent years, most of the biosynthetic pathways have been elucidated. Gene clusters from several ergot alkaloid producers have been identified by genome mining and the functions of many of those genes have been demonstrated by knock-out experiments or biochemical investigations of the overproduced enzymes.
[Mh] Termos MeSH primário: Ascomicetos/metabolismo
Vias Biossintéticas
Alcaloides de Claviceps/biossíntese
[Mh] Termos MeSH secundário: Aspergillus/metabolismo
Claviceps/metabolismo
Ergolinas/metabolismo
Ácido Lisérgico/metabolismo
Família Multigênica
Penicillium/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Ergolines); 0 (Ergot Alkaloids); 32X6F73RE2 (chanoclavine); ITO20DAO7J (Lysergic Acid)
[Em] Mês de entrada:1509
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141217
[St] Status:MEDLINE
[do] DOI:10.3390/toxins6123281


  5 / 110 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:25107976
[Au] Autor:Robinson SL; Panaccione DG
[Ad] Endereço:West Virginia University, Division of Plant and Soil Sciences, Genetics and Developmental Biology Program, Morgantown, West Virginia, USA.
[Ti] Título:Heterologous expression of lysergic acid and novel ergot alkaloids in Aspergillus fumigatus.
[So] Source:Appl Environ Microbiol;80(20):6465-72, 2014 Oct.
[Is] ISSN:1098-5336
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Different lineages of fungi produce distinct classes of ergot alkaloids. Lysergic acid-derived ergot alkaloids produced by fungi in the Clavicipitaceae are particularly important in agriculture and medicine. The pathway to lysergic acid is partly elucidated, but the gene encoding the enzyme that oxidizes the intermediate agroclavine is unknown. We investigated two candidate agroclavine oxidase genes from the fungus Epichloë festucae var. lolii × Epichloë typhina isolate Lp1 (henceforth referred to as Epichloë sp. Lp1), which produces lysergic acid-derived ergot alkaloids. Candidate genes easH and cloA were expressed in a mutant strain of the mold Aspergillus fumigatus, which typically produces a subclass of ergot alkaloids not derived from agroclavine or lysergic acid. Candidate genes were coexpressed with the Epichloë sp. Lp1 allele of easA, which encodes an enzyme that catalyzed the synthesis of agroclavine from an A. fumigatus intermediate; the agroclavine then served as the substrate for the candidate agroclavine oxidases. Strains expressing easA and cloA from Epichloë sp. Lp1 produced lysergic acid from agroclavine, a process requiring a cumulative six-electron oxidation and a double-bond isomerization. Strains that accumulated excess agroclavine (as a result of Epichloë sp. Lp1 easA expression in the absence of cloA) metabolized it into two novel ergot alkaloids for which provisional structures were proposed on the basis of mass spectra and precursor feeding studies. Our data indicate that CloA catalyzes multiple reactions to produce lysergic acid from agroclavine and that combining genes from different ergot alkaloid pathways provides an effective strategy to engineer important pathway molecules and novel ergot alkaloids.
[Mh] Termos MeSH primário: Aspergillus fumigatus/genética
Aspergillus fumigatus/metabolismo
Epichloe/enzimologia
Alcaloides de Claviceps/biossíntese
Proteínas Fúngicas/genética
Ácido Lisérgico/metabolismo
[Mh] Termos MeSH secundário: Epichloe/genética
Ergolinas/metabolismo
Alcaloides de Claviceps/química
Proteínas Fúngicas/metabolismo
Microbiologia Industrial/métodos
Espectrometria de Massas
Oxigenases de Função Mista/genética
Oxigenases de Função Mista/metabolismo
Estrutura Molecular
Mutação
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, NON-P.H.S.
[Nm] Nome de substância:
0 (Ergolines); 0 (Ergot Alkaloids); 0 (Fungal Proteins); A8SW57GO7T (agroclavine); EC 1.- (Mixed Function Oxygenases); ITO20DAO7J (Lysergic Acid)
[Em] Mês de entrada:1604
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140810
[St] Status:MEDLINE
[do] DOI:10.1128/AEM.02137-14


  6 / 110 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24361048
[Au] Autor:Havemann J; Vogel D; Loll B; Keller U
[Ad] Endereço:Institut für Chemie, Arbeitsgruppe Biochemie und Molekulare Biologie, Technische Universität Berlin, Müller-Breslau-Strasse 10, Berlin-Charlottenburg 10623, Germany.
[Ti] Título:Cyclolization of D-lysergic acid alkaloid peptides.
[So] Source:Chem Biol;21(1):146-55, 2014 Jan 16.
[Is] ISSN:1879-1301
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The tripeptide chains of the ergopeptines, a class of pharmacologically important D-lysergic acid alkaloid peptides, are arranged in a unique bicyclic cyclol based on an amino-terminal α-hydroxyamino acid and a terminal orthostructure. D-lysergyl-tripeptides are assembled by the nonribosomal peptide synthetases LPS1 and LPS2 of the ergot fungus Claviceps purpurea and released as N-(D-lysergyl-aminoacyl)-lactams. We show total enzymatic synthesis of ergopeptines catalyzed by a Fe²âº/2-ketoglutarate-dependent dioxygenase (EasH) in conjunction with LPS1/LPS2. Analysis of the reaction indicated that EasH introduces a hydroxyl group into N-(D-lysergyl-aminoacyl)-lactam at α-C of the aminoacyl residue followed by spontaneous condensation with the terminal lactam carbonyl group. Sequence analysis revealed that EasH belongs to the wide and diverse family of the phytanoyl coenzyme A hydroxylases. We provide a high-resolution crystal structure of EasH that is most similar to that of phytanoyl coenzyme A hydroxylase, PhyH, from human.
[Mh] Termos MeSH primário: Dioxigenases/metabolismo
Ergotamina/biossíntese
Ergotamina/química
Ácido Lisérgico/química
Ácido Lisérgico/metabolismo
Peptídeos/química
Peptídeos/metabolismo
[Mh] Termos MeSH secundário: Biocatálise
Claviceps/enzimologia
Ciclização
Di-Hidroergotamina/química
Di-Hidroergotamina/metabolismo
Dioxigenases/química
Ergolinas/química
Ergolinas/metabolismo
Seres Humanos
Hidroxilação
Oxigenases de Função Mista/química
Oxigenases de Função Mista/metabolismo
Modelos Moleculares
Peptídeo Sintases/metabolismo
Conformação Proteica
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Ergolines); 0 (Peptides); 2J09Y26C6I (ergotoxine); 436O5HM03C (Dihydroergotamine); EC 1.- (Mixed Function Oxygenases); EC 1.13.11.- (Dioxygenases); EC 6.3.2.- (Peptide Synthases); EC 6.3.2.- (non-ribosomal peptide synthase); ITO20DAO7J (Lysergic Acid); PR834Q503T (Ergotamine)
[Em] Mês de entrada:1501
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:131224
[St] Status:MEDLINE


  7 / 110 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24115177
[Au] Autor:Himmelsbach M; Ferdig M; Rohrer T
[Ad] Endereço:Institute of Analytical Chemistry, Johannes Kepler University Linz, Linz, Austria.
[Ti] Título:Analysis of paspalic acid, lysergic acid, and iso-lysergic acid by capillary zone electrophoresis with UV- and quadrupole time-of-flight mass spectrometric detection.
[So] Source:Electrophoresis;35(9):1329-33, 2014 May.
[Is] ISSN:1522-2683
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:CZE was investigated for separation of lysergic, iso-lysergic, and paspalic acid. BGEs were optimized regarding separation selectivity and analysis time as well as MS compatibility. BGEs using asparagine, Na-tetraborate, or ammonium acetate yielded satisfactory resolution when 40% of methanol was added and the pH adjusted to 8.3. Applying acidic BGEs also allowed fast separations but the poor stability under acidic conditions of the selected analytes prevented further use. With ultraviolet (UV) detection, LODs were 0.45 and 0.40 mg/L for paspalic acid and lysergic acid, respectively. Run-to-run precision of peak areas was 1.8% for lysergic acid and 1.9% for paspalic acid and day-to-day precision was 2.4 and 4.0%, respectively. When MS detection was used LODs improved to 0.09 mg/L for paspalic acid and 0.07 mg/L for lysergic acid. Repeatability results were excellent for a CZE-MS method without internal standard ranging from 3.4% for the highest standard concentration to 5.8% for the lowest concentration. Recovery and matrix effects were studied with samples taken from different stages of the manufacturing process and yielded an average recovery of 100.8% and a RSD of 5.7%.
[Mh] Termos MeSH primário: Eletroforese Capilar/métodos
Ácido Lisérgico/análogos & derivados
Ácido Lisérgico/análise
Espectrometria de Massas/métodos
[Mh] Termos MeSH secundário: Claviceps
Fermentação
Limite de Detecção
Modelos Lineares
Ácido Lisérgico/química
Ácido Lisérgico/metabolismo
Reprodutibilidade dos Testes
Espectrofotometria Ultravioleta
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
ITO20DAO7J (Lysergic Acid)
[Em] Mês de entrada:1412
[Cu] Atualização por classe:140422
[Lr] Data última revisão:
140422
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:131012
[St] Status:MEDLINE
[do] DOI:10.1002/elps.201300224


  8 / 110 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24111583
[Au] Autor:Liu Q; Zhang YA; Xu P; Jia Y
[Ad] Endereço:State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University , 38 Xueyuan Road, Beijing 100191, China.
[Ti] Título:Total synthesis of (+)-lysergic acid.
[So] Source:J Org Chem;78(21):10885-93, 2013 Nov 01.
[Is] ISSN:1520-6904
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We report the enantioselective total synthesis of (+)-lysergic acid using two different strategies, which featured three metal-catalyzed reactions for the construction of the BCD three rings, involving Pd-catalyzed indole synthesis for the construction of the B ring, a ring-closing metathesis reaction for the formation of the D ring, and an intramolecular Heck reaction to forge the C ring. In synthetic strategy I, the synthesis was achieved in 20 steps following the ring construction sequence of BDC. In synthetic strategy II, the synthetic route was shortened to only 12 steps by following the ring construction sequence of DBC and using a 4-chlorotryptophan derivative for the intramolecular Heck reaction. Moreover, we also discussed an unsuccessful synthetic strategy.
[Mh] Termos MeSH primário: Ácido Lisérgico/síntese química
[Mh] Termos MeSH secundário: Ciclização
Ácido Lisérgico/química
Estrutura Molecular
Estereoisomerismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
ITO20DAO7J (Lysergic Acid)
[Em] Mês de entrada:1406
[Cu] Atualização por classe:131101
[Lr] Data última revisão:
131101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:131012
[St] Status:MEDLINE
[do] DOI:10.1021/jo4018777


  9 / 110 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:23919892
[Au] Autor:Umezaki S; Yokoshima S; Fukuyama T
[Ad] Endereço:Graduate School of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
[Ti] Título:Total synthesis of lysergic acid.
[So] Source:Org Lett;15(16):4230-3, 2013 Aug 16.
[Is] ISSN:1523-7052
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:A total synthesis of lysergic acid was accomplished. Key features of our synthesis include stereoselective construction of the stereogenic centers at the allylic positions by using the Evans aldol reaction, and a sequential process with a ring-closing metathesis and an intramolecular Heck reaction to construct the C and D rings.
[Mh] Termos MeSH primário: Ácido Lisérgico/química
Ácido Lisérgico/síntese química
[Mh] Termos MeSH secundário: Ciclização
Estrutura Molecular
Estereoisomerismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
ITO20DAO7J (Lysergic Acid)
[Em] Mês de entrada:1401
[Cu] Atualização por classe:140408
[Lr] Data última revisão:
140408
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:130808
[St] Status:MEDLINE
[do] DOI:10.1021/ol4019562


  10 / 110 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22640760
[Au] Autor:Ross S
[Ad] Endereço:Division of Alcoholism and Drug Abuse, Bellevue Hospital Center and the New York University School of Medicine, New York, NY 10016, USA. Stephen.ross@nyumc.org
[Ti] Título:Serotonergic hallucinogens and emerging targets for addiction pharmacotherapies.
[So] Source:Psychiatr Clin North Am;35(2):357-74, 2012 Jun.
[Is] ISSN:1558-3147
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Only time will tell if serotonergic hallucinogen-assisted psychotherapy treatment paradigms for SUDs will prove to be safe and effective in double-blind, placebo-controlled clinical trials. If they are, they would truly constitute a novel psychopharmacologic-psychosocial treatment paradigm to treat addictive disorders, although the risk of adverse psychological events would have to be controlled through a careful screening process and the risk of misuse of the substances or developing use syndromes would have to be considered, although the overall risk would be low because, as mentioned, SHs are unlike all other drugs of abuse in that they do not appear to produce dependence syndromes. There effects on the NA and DA range from inhibition to slight activation, all this without producing addiction. The ability of these medicinal tools to treat a range of addictive, psychiatric, and existential disorders is remarkable in scope and possibility. They truly represent a potential paradigmatic shift within the field of psychiatry, too interesting to not explore further.
[Mh] Termos MeSH primário: Comportamento Aditivo/tratamento farmacológico
Alucinógenos/farmacologia
Fitoterapia
Agonistas de Receptores 5-HT2 de Serotonina/farmacologia
Síndrome de Abstinência a Substâncias/prevenção & controle
Transtornos Relacionados ao Uso de Substâncias/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Animais
Comportamento Aditivo/metabolismo
Comportamento Aditivo/fisiopatologia
Ensaios Clínicos como Assunto
Cognição/efeitos dos fármacos
Dopamina/metabolismo
Agonistas de Dopamina/farmacologia
Glutamatos/metabolismo
Alucinógenos/química
Alucinógenos/classificação
Seres Humanos
Ibogaína/farmacologia
Ácido Lisérgico/farmacologia
Plasticidade Neuronal/efeitos dos fármacos
Núcleo Accumbens/metabolismo
Córtex Pré-Frontal/efeitos dos fármacos
Córtex Pré-Frontal/metabolismo
Córtex Pré-Frontal/fisiopatologia
Psilocibina/farmacologia
Religião
Recompensa
Agonistas de Receptores 5-HT2 de Serotonina/química
Agonistas de Receptores 5-HT2 de Serotonina/classificação
Transtornos Relacionados ao Uso de Substâncias/metabolismo
Transtornos Relacionados ao Uso de Substâncias/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dopamine Agonists); 0 (Glutamates); 0 (Hallucinogens); 0 (Serotonin 5-HT2 Receptor Agonists); 2RV7212BP0 (Psilocybin); 3S814I130U (Ibogaine); ITO20DAO7J (Lysergic Acid); VTD58H1Z2X (Dopamine)
[Em] Mês de entrada:1209
[Cu] Atualização por classe:161125
[Lr] Data última revisão:
161125
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120530
[St] Status:MEDLINE
[do] DOI:10.1016/j.psc.2012.04.002



página 1 de 11 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde